Gamida Cell Ltd.'s NiCord® Demonstrates Successful Engraftment in Patients With Hematological Malignancies in Phase I/II Study
2/15/2013 9:17:49 AM
More...
|
Gamida Cell Ltd. Reports Success in Blood Cancer Trial
2/4/2013 7:14:23 AM
More...
|
Gamida Cell Ltd. Completes Enrollment for Phase I/II Study of Second Pipeline Product NiCord® for Hematological Malignancies
9/19/2012 8:47:42 AM
More...
|
Gamida Cell Ltd. Raises $10 Million to Progress Phase III-Stage Hematologic Cancer Cell Therapy
5/15/2012 6:56:31 AM
More...
|
Gamida Cell Ltd.-Teva Pharmaceutical Industries Limited (TEVA) Joint Venture Concludes Enrollment for the Phase III Study of StemEx®, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
2/13/2012 6:13:57 AM
More...
|
The Gamida Cell Ltd.-Teva Pharmaceutical Industries Limited (TEVA) Joint Venture Receives Green Light From the Data Monitoring Committee to Continue the Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
7/12/2011 9:12:41 AM
More...
|
The Gamida Cell Ltd.-Teva Pharmaceutical Industries Limited (TEVA) Joint Venture Receives FDA Fast Track Designation for StemEx(R) for Leukemia and Lymphoma
6/21/2010 7:21:35 AM
More...
|
Gamida Cell Ltd.: Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
2/10/2010 9:30:08 AM
More...
|
Gamida Cell Ltd.: European Medicines Evaluation Agency Waives Requirement to Test StemEx(R) in Paediatric Patients 17 Years of Age and Under
1/19/2010 10:21:04 AM
More...
|
Gamida Cell Ltd. Announces Feasibility Study With Weill Cornell Medical College
12/2/2009 11:38:18 AM
More...
|
|